AIM: The purpose of this work is to determine if tumor-tropic neural stem cells (NSCs) can improve the tumor-selective distribution and retention of nanoparticles (NPs) within invasive brain tumors. MATERIALS & METHODS: Streptavidin-conjugated, polystyrene NPs are surface-coupled to biotinylated human NSCs. These NPs are large (798 nm), yet when conjugated to tropic cells, they are too large to passively diffuse through brain tissue or cross the blood-tumor barrier. NP distribution and retention was quantified 4 days after injections located either adjacent to an intracerebral glioma, in the contralateral hemisphere, or intravenously. RESULTS & CONCLUSION: In all three in vivo injection paradigms, NSC-coupled NPs exhibited significantly improved tumor-selective distribution and retention over free-NP suspensions. These results provide proof-of-principle that NSCs can facilitate the tumor-selective distribution of NPs, a platform useful for improving intracranial drug delivery.
AIM: The purpose of this work is to determine if tumor-tropic neural stem cells (NSCs) can improve the tumor-selective distribution and retention of nanoparticles (NPs) within invasive brain tumors. MATERIALS & METHODS: Streptavidin-conjugated, polystyrene NPs are surface-coupled to biotinylated human NSCs. These NPs are large (798 nm), yet when conjugated to tropic cells, they are too large to passively diffuse through brain tissue or cross the blood-tumor barrier. NP distribution and retention was quantified 4 days after injections located either adjacent to an intracerebral glioma, in the contralateral hemisphere, or intravenously. RESULTS & CONCLUSION: In all three in vivo injection paradigms, NSC-coupled NPs exhibited significantly improved tumor-selective distribution and retention over free-NP suspensions. These results provide proof-of-principle that NSCs can facilitate the tumor-selective distribution of NPs, a platform useful for improving intracranial drug delivery.
Authors: Uwe M Fischer; Matthew T Harting; Fernando Jimenez; Werner O Monzon-Posadas; Hasen Xue; Sean I Savitz; Glen A Laine; Charles S Cox Journal: Stem Cells Dev Date: 2009-06 Impact factor: 3.272
Authors: Atique U Ahmed; Matthew A Tyler; Bart Thaci; Nikita G Alexiades; Yu Han; Ilya V Ulasov; Maciej S Lesniak Journal: Mol Pharm Date: 2011-06-30 Impact factor: 4.939
Authors: Mateo Ziu; Nils Ole Schmidt; Theresa G Cargioli; Karen S Aboody; Peter McL Black; Rona S Carroll Journal: J Neurooncol Date: 2006-04-06 Impact factor: 4.130
Authors: Katharina Hansen; Franz-Josef Müller; Markus Messing; Frank Zeigler; Jeanne F Loring; Katrin Lamszus; Manfred Westphal; Nils Ole Schmidt Journal: Neuro Oncol Date: 2010-02-14 Impact factor: 12.300
Authors: Alice B Brown; Wendy Yang; Nils O Schmidt; Rona Carroll; Kim K Leishear; Nikolai G Rainov; Peter M Black; Xandra O Breakefield; Karen S Aboody Journal: Hum Gene Ther Date: 2003-12-10 Impact factor: 5.695
Authors: Stephen E Kendall; Joseph Najbauer; Heather F Johnston; Marianne Z Metz; Shan Li; Marisa Bowers; Elizabeth Garcia; Seung U Kim; Michael E Barish; Karen S Aboody; Carlotta A Glackin Journal: Stem Cells Date: 2008-03-13 Impact factor: 6.277
Authors: Shengwen Calvin Li; Mustafa H Kabeer; Long T Vu; Vic Keschrumrus; Hong Zhen Yin; Brent A Dethlefs; Jiang F Zhong; John H Weiss; William G Loudon Journal: World J Stem Cells Date: 2014-09-26 Impact factor: 5.326
Authors: Casey A Maguire; Servio H Ramirez; Steven F Merkel; Miguel Sena-Esteves; Xandra O Breakefield Journal: Neurotherapeutics Date: 2014-10 Impact factor: 7.620
Authors: Jana Portnow; Timothy W Synold; Behnam Badie; Revathiswari Tirughana; Simon F Lacey; Massimo D'Apuzzo; Marianne Z Metz; Joseph Najbauer; Victoria Bedell; Tien Vo; Margarita Gutova; Paul Frankel; Mike Chen; Karen S Aboody Journal: Clin Cancer Res Date: 2016-12-15 Impact factor: 12.531